Chronic Kidney Disease Market to Register Moderate Growth over 2023

Pune, India, September, 2018 /press release/- Market Research Future Published a Half-Cooked Research Report on Chronic Kidney Disease Market Research Report.

Market Synopsis:

Market Research Future (MRFR)’s latest study reveals that the global chronic kidney disease market is set to expand moderately at a CAGR of 5.2% during the forecast period 2017 to 2023. The investments into development of new treatments coupled with rising prevalence of kidney diseases are expected to drive the growth of the market in the next couple of years. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the U.S., has stated that nearly 14% of the overall population is affected by chronic kidney diseases.

An upsurge in the number of biopsy procedures is witnessed in the recent times and is likely to perpetuate in the forthcoming years. This, in turn, is expected to have a positive influence on the proliferation of the chronic kidney disease market. Furthermore, the rising burden of diabetes has intensified the preventive care treatment for kidney diseases. It is anticipated to have a strong impact on the growth of the market. Other factors responsible for the growth of the market are rising healthcare expenditure, developing healthcare sector, growing research & development activities, technological advancements in the healthcare sector, etc.

Market segmentation:

By diagnosis, the chronic kidney disease market is segmented into blood test, urine test, imaging test, and kidney biopsy.

By treatment, the global chronic kidney disease market has been segmented into drugs, dialysis, and kidney transplant. The drugs segment is further sub-segmented into ace inhibitors, angiotensin-ii receptor blockers, calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.

By indication, the chronic kidney disease market is segmented into Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, and others.

By end-user, the global chronic kidney disease market has been segmented into hospitals and clinics, diagnostic centers, and others.

Access Report @ https://www.marketresearchfuture.com/reports/chronic-kidney-disease-market-5744

Regional Analysis

By region, the global chronic kidney disease market has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas is poised to exhibit a healthy growth throughout the forecast period. The growth is attributable to the increasing patient pool, rising demand for alternative treatments, extensive use of diagnostic tests, etc.

Europe is an important growth pocket of the chronic kidney disease market. The factors responsible for favoring the expansion of the regional market include rising awareness about risk factors associated with kidney diseases, booming medical device industry, exponential diabetic population, huge investments in the medical device sector, etc. Additionally, rising government support and funding for research & development is further likely to augment the regional chronic kidney disease market over the assessment period.

Asia Pacific is projected to strike a relatively higher CAGR owing to the large-scale prevalence of diabetes and cardiovascular diseases. The growth of the region can be ascribed to the presence of developed healthcare infrastructure, rapid advancements in the healthcare sector, the presence of skilled healthcare professionals, etc.

The Middle East & Africa accounts for the least share of the chronic kidney disease market. It is due to the limited technological penetration and lack of awareness.

Competitive Dashboard:

Some of the key players profiled in the report are Beckman Coulter, F. Hoffmann-La Roche Ltd, Abbott, Siemens, Sysmex, ACON Laboratories, Inc., URIT Medical, 77 Elektronika, Randox Laboratories, Teva Pharmaceutical Industries Ltd., Amgen Inc., Nova Biomedical, ARKRAY, OPTI Medical, AstraZeneca Plc, Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Kissei Pharmaceutical Co. Ltd.

Industry Developments:

In May 2018, Baxter, a healthcare company, inked a partnership with International Society of Nephrology to advance awareness and therapy for patients with chronic kidney disease in low and middle-income countries.

In July 2018, Otsuka, a pharmaceutical company, acquired renal denervation device developed by ReCor Medical.